U.S. Markets closed

Akari Therapeutics, Plc (AKTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8100-0.0500 (-2.69%)
At close: 4:00PM EDT
Sign in to post a message.
  • j
    jay
    Finally get fast tracked and it’s down? Look for the spike up any day now.
    Bullish
  • b
    blue
    with the stock market crashing today see ascarycarymassive massive profit sellingdumpingback below $2 today beveryvery afraidtolossalotlot more moneyget what youcan now orget alotlot less then $2 sooon
  • P
    Patrick
    Go up
    Bullish
  • M
    M
    On a slow trading day - is this enough to generate interest?
    Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid 4/28/2021 8:00:14 AM
  • A
    Anonymous
    With this volume we are going to $3 by EOD
  • H
    H M A
    still halted
    Bullish
  • L
    Leandra
    I can't find any news but I doubled my position over the weekend just to be safe.
  • R
    Rachel
    AKTX has been a roller coaster over the past week. Congrats to all of those who made money on this one. Friday didn’t look great but it is looking primed for a bounce in the Premarket. I am going to keep watching this one and in the meantime I have been watching small cap stocks in hopes that I can find another runner before the run. One I have been watching lately is like Amazon Prime but they will get you anything you want even if it is not on the site. http://billion.finance/OnDemand"
    Latest News: ParcelPal (PTNYF) (PKG) Welcomes Brian Storseth to the Board of Directors and Acting Chairman Technology has evolved over the years, and so have online websites and apps. Growing food delivery apps are the newest trend, expanding revenue
    Latest News: ParcelPal (PTNYF) (PKG) Welcomes Brian Storseth to the Board of Directors and Acting Chairman Technology has evolved over the years, and so have online websites and apps. Growing food delivery apps are the newest trend, expanding revenue
    billion.finance
  • S
    Shlomo
    Market Cap $70 million /Cash balance $18,3 Million / 2 attractive Phase 3 Programs / Results from Covid 19 trial coming anyday now = Dirt cheap Biotech with SIGNIFICANT upside ...GL
    https://assets.wallstreet-online.de/_media/8763/board/20210106124138-screenshot-2021-01-06-ac4c08a2-cda9-4331-8033-c0b.png
    Bullish
  • F
    Forest Gump
    Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
    www.globenewswire.com
  • L
    Leandra
    Whole market red. This still green.
  • N
    Neal
    Not that I'm looking for deep rooted financial advise here, but how can a company release positive news, positive outcome from a meeting, head on to Phase 3, be up 40% in the premarket...and just now go red on the day. I get that it'll take more work but seriously...negative on the day???
  • g
    gautam
    ha ha ha.. there is a Mr. Big V and a Mr. Small v.. who do we trust... it is like a good cop and bad cop. One says the company will burn its cash and other says it will go upto 8-10 and then $20. Here is what they said in their earnings call:

    Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease Area Index (BPDAI) score and blistering in ongoing Phase II clinical trial
    Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) expected to start Q4 2019
    Initial data on atopic keratoconjunctivitis (AKC) and pre-clinical back of the eye program to be presented at Association for Research in Vision and Ophthalmology (ARVO) 2019
    Long-term clinical study with Nomacopan (Coversin) continues to yield encouraging safety data

    With all that if you think they will burn cash with no investors then you are just ANOTHER FEARMONGER here who talks with no facts.

    How do you know they will burn cash in 2 quarters? Do you know their Burn rate? Have you seen their cash holdings? Revenue? do you know how much is their spend in terms of SG&A, expenses (salaries etc)?

    So, please share details based on facts and not just say someting.. your words matter and they affect people and opinions. Please be responsible. If I mentioned something which isnt write, I am sorry.. correct me!
  • J
    Joe
    Only 9 Million Float, FDA Fast Track Announced This Morning, and Already Over 20 Million Traded, Let's Go Longs, This Can Go to $6.00 Fast and EASY.
  • P
    President XI
    I didn't think I would get shares this cheap again lol - fundamentals haven't changed so its a pretty easy decision but would like to see the namocopan P3 interims to be sure which I thought would be out per the data disclosure blackout deadline for the EHA conference which was over at 830 CEST today (around midnight this morning in NA).
  • J
    JP
    34+ million traded yesterday = 4x the float and it goes up $1.

    3+million traded today and it’s down 0.75. Strange.
  • s
    silverman
    Big updates coming up with significant unmet medical needs
  • R
    Rodge
    Not Only Is This a Low Floater , only 9 Million Float But The Drug Is Orphan Condition , Unmet Medical Need Drug.
  • P
    Philosophy
    for those who missed selling at $3.00 , keep onto your holdings. 30million buyers are still there(maybe just one buyer?) and this little company is making progress towards its FDA approval. At $1.80 the risk of continued losing is minimal. Don't sell now!
  • G
    Guerilla Trades
    long